Pharmacotherapy of diabetes mellitus in patients with heart
failure-a nation-wide analysis of contemporary treatment

J 2023

Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment

VICHA, Marek, Tomas SKALA, Libor JELINEK, Ludek PAVLU, Jiří JARKOVSKÝ et. al.

Základní údaje

Originální název

Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment

Autoři

VICHA, Marek (203 Česká republika), Tomas SKALA (203 Česká republika, garant), Libor JELINEK (203 Česká republika), Ludek PAVLU (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Ladislav DUŠEK (203 Česká republika, domácí), Klára BENEŠOVÁ (203 Česká republika, domácí) a Milos TABORSKY (203 Česká republika)

Vydání

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 0.900 v roce 2022

Kód RIV

RIV/00216224:14110/23:00129948

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5507/bp.2021.069

UT WoS

000731342200001

Klíčová slova anglicky

diabetes mellitus; heart failure; pharmacotherapy; National Register of Paid Health Services (NRHZS)

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 1. 2024 09:51, Mgr. Tereza Miškechová

Anotace

V originále

Aim. Retrospective national sub-analysis of antidiabetic pharmacotherapy in patients with diabetes mellitus (DM) and heart failure (HF) based on data reported to the National Register of Paid Health Services in the Czech Republic between 2012-2018. Methodology and Results. In 2012, there were 75,022 patients with HF and DM (i.e. 42.5% of patients with HF), 6 years later 117,265 (i.e. 41.0% of HF patients in 2018). The most represented antidiabetic drug was metformin (45.6%). Of the insulins and analogues, glargine showed the largest positive trend (5.8% 2012; 14.8% 2018). Empagliflozin was the most prescribed SGLT-2 inhibitor (1.8% in 2018). A decrease in prescribing was observed for saxagliptin (0.5% 2012; 0.1% 2018) and for sulfonylurea derivates - gliclazide (13.0% 2012; 10.3% in 2018) and glimepiride (12.9% 2012; 9.0% 2018). Linagliptin was the most prescribed dipeptidyl peptidase inhibitor (0.7% 2012; 6.8% 2018). Conclusion. In the Czech Republic, between 2012 and 2008, there was an increase in prevalence of patients with heart failure and concomitant diabetes mellitus, their proportion being similar. In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.

Citovat

VICHA, Marek, Tomas SKALA, Libor JELINEK, Ludek PAVLU, Jiří JARKOVSKÝ, Ladislav DUŠEK, Klára BENEŠOVÁ a Milos TABORSKY. Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2023, roč. 167, č. 2, s. 177-184. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2021.069.

@article{1834417,
   author = {Vicha, Marek and Skala, Tomas and Jelinek, Libor and Pavlu, Ludek and Jarkovský, Jiří and Dušek, Ladislav and Benešová, Klára and Taborsky, Milos},
   article_location = {Olomouc},
   article_number = {2},
   doi = {http://dx.doi.org/10.5507/bp.2021.069},
   keywords = {diabetes mellitus; heart failure; pharmacotherapy; National Register of Paid Health Services (NRHZS)},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers, Olomouc: Palacky University},
   title = {Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment},
   url = {https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3089},
   volume = {167},
   year = {2023}
}

TY  - JOUR
ID  - 1834417
AU  - Vicha, Marek - Skala, Tomas - Jelinek, Libor - Pavlu, Ludek - Jarkovský, Jiří - Dušek, Ladislav - Benešová, Klára - Taborsky, Milos
PY  - 2023
TI  - Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment
JF  - Biomedical Papers, Olomouc: Palacky University
VL  - 167
IS  - 2
SP  - 177-184
EP  - 177-184
PB  - Palacky University
SN  - 12138118
KW  - diabetes mellitus
KW  - heart failure
KW  - pharmacotherapy
KW  - National Register of Paid Health Services (NRHZS)
UR  - https://biomed.papers.upol.cz/corproof.php?tartkey=bio-000000-3089
N2  - Aim. Retrospective national sub-analysis of antidiabetic pharmacotherapy in patients with diabetes mellitus (DM) and heart failure (HF) based on data reported to the National Register of Paid Health Services in the Czech Republic between 2012-2018. Methodology and Results. In 2012, there were 75,022 patients with HF and DM (i.e. 42.5% of patients with HF), 6 years later 117,265 (i.e. 41.0% of HF patients in 2018). The most represented antidiabetic drug was metformin (45.6%). Of the insulins and analogues, glargine showed the largest positive trend (5.8% 2012; 14.8% 2018). Empagliflozin was the most prescribed SGLT-2 inhibitor (1.8% in 2018). A decrease in prescribing was observed for saxagliptin (0.5% 2012; 0.1% 2018) and for sulfonylurea derivates - gliclazide (13.0% 2012; 10.3% in 2018) and glimepiride (12.9% 2012; 9.0% 2018). Linagliptin was the most prescribed dipeptidyl peptidase inhibitor (0.7% 2012; 6.8% 2018). Conclusion. In the Czech Republic, between 2012 and 2008, there was an increase in prevalence of patients with heart failure and concomitant diabetes mellitus, their proportion being similar. In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.
ER  -

VICHA, Marek, Tomas SKALA, Libor JELINEK, Ludek PAVLU, Jiří JARKOVSKÝ, Ladislav DUŠEK, Klára BENEŠOVÁ a Milos TABORSKY. Pharmacotherapy of diabetes mellitus in patients with heart failure-a nation-wide analysis of contemporary treatment. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2023, roč.~167, č.~2, s.~177-184. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2021.069.

Podrobný výpis o publikaci